2024-09-16 - Analysis Report
## REGN Stock Analysis Report

**Company Overview:** Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company focused on the discovery, development, and commercialization of life-transforming medicines for serious diseases. 

**1. Performance vs. S&P 500:**

* **Cumulative Return:** REGN has a cumulative return of 152.58%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 88.73%.
* **Performance Gap:** The current performance gap between REGN and VOO is 63.85%, which is a substantial difference. This represents a relative strength of 90.24% compared to the historical range of performance differences.

**2. Recent Price Movement:**

* **Closing Price:** $1153.35
* **Moving Averages:**
    * 5-day: $1148.08
    * 20-day: $1173.76
    * 60-day: $1109.84

The recent price action indicates a slight downward trend, with the closing price below the 5-day and 20-day moving averages. However, the stock is still trading above the 60-day moving average, indicating a longer-term uptrend.

**3. Technical Indicators:**

* **RSI:** 36.25 – The RSI is below 50, suggesting that the stock is currently oversold and could be due for a rebound.
* **PPO:** -0.63 – The PPO is negative, indicating that the stock is experiencing a downward momentum.
* **Delta_Previous_Relative_Divergence:** -9.76 – This indicates a short-term downward trend in the relative strength of REGN compared to the S&P 500.
* **Expected_Return:** 7.38% – This suggests a potential for a 7.38% return on investment over the next five years. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

The most recent earnings report for 2024-08-01 showed an EPS of 13.25 and revenue of 3.55 Billion dollars. While the company has consistently exceeded revenue expectations in recent quarters, the latest EPS was slightly lower than the analyst consensus estimate. This could explain the recent downward price movement. However, Regeneron remains a profitable and well-established company with a strong pipeline of promising drug candidates. 

**5. Overall Analysis:**

REGN has historically outperformed the S&P 500, with a significant gap in cumulative returns. Despite the recent downward trend, the stock remains above its 60-day moving average, suggesting a longer-term uptrend. Technical indicators indicate a potential oversold situation and an opportunity for a rebound, although the short-term trend is bearish. While the latest earnings report showed a slightly lower EPS than expected, Regeneron remains a fundamentally strong company with a robust pipeline of drug candidates.

**6. Conclusion:**

Regeneron Pharmaceuticals (REGN) presents a compelling investment opportunity. While the stock is experiencing a short-term downward trend, its long-term performance, strong fundamentals, and promising pipeline suggest a potential for future growth. Investors should closely monitor the company's future earnings reports and upcoming drug approvals to assess its future prospects.
